| Newswire Search | Up to 90 Days | 65 stories | 56 Publishers |
| Topic | # Mentions | Topic Reach |
|---|---|---|
| novo nordisk | 27 | - |
| pfizer | 5 | - |
| glp | 3 | - |
| Byline | Articles Written | Avg Reach |
|---|---|---|
| n/a | 32 | - |
| Alex Harring | 2 | - |
| Kate Ashford, CSA® | 2 | - |
| President Donald Trump | 2 | - |
| Emily Mullin | 1 | - |
| Reuters | 1 | - |
| ABMN Staff | 1 | - |
| Jamie Gumbrecht, CNN | 1 | - |
| Jamie Gumbrecht | 1 | - |
| Tom Murphy | 1 | - |
| Elsa Ohlen | 1 | - |
| PT Jyothi Datta | 1 | - |
| Anne D'Innocenzio, Associated Press | 1 | - |
| ANNE D'INNOCENZIO - AP Business Writer | 1 | - |
| Bloomberg News (TNS) | 1 | - |
| Alice Park | 1 | - |
| CNN Newsource | 1 | - |
| Beiyi SEOW AFP | 1 | - |
| Associated Press | 1 | - |
| The Associated Press | 1 | - |
Execution: 17.35 Seconds. 125.58 mb used.
Novo Nordisk's new obesity pill, Alphabet's data center deal, the end of EV euphoria and more in Morning Squawk
FDA approves Wegovy weight-loss pill in first alternative to injectable GLP-1s
Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers
Healthify eyes more weight-loss drugmaker tie-ups after Novo Nordisk pact